ReviewGalen medical journal2025
Daratumumab Versus Control Treatment: A Systematic Review and Meta-analysis Study of Survival Outcomes Among Multiple Myeloma Patients : Survival Outcomes of Multiple Myeloma Treatment with Daratumumab.
Review in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This meta-analysis aimed to evaluate the efficacy of Daratumumab compared to control treatments in multiple myeloma across subgroups, including relapsed or refractory (RRMM), newly diagnosed transplant-eligible (ND/ESCT), and transplant-ineligible (ND/ISCT) patients. Materials and Methods: A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. Randomized controlled trials and comparative studies evaluating Daratumumab versus control treatments in multiple myeloma patients were included. A random-effects model was employed to calculate pooled effect estimates of overall response rate (ORR), progression or death (PRD), minimum residual disease (MRD) negativity, and mortality. Results: The analysis included data from 35 studies, 21 studies (n=7,604 patients) in the RRMM subgroup, 12 studies (n=10,216 patients) in the ND/ISCT subgroup, and 6 studies (n=4,619 patients) in the ND/ESCT subgroup, comprising 22,439 patients (including healthy controls). Daratumumab significantly improved ORR (OR: 2.58, 95% CI: 2.26-2.93, P0.01) and MRD negativity rates across all subgroups. PRD risk was lower in the Daratumumab group (RD: -0.14, 95% CI: -0.16 to -0.12), with consistent efficacy across RRMM, ND/ESCT, and ND/ISCT patients. Conclusion: This meta-analysis confirms Daratumumab's significant efficacy across multiple patient subgroups, providing broad clinical benefits in multiple myeloma treatment. While some heterogeneity and potential publication bias were observed, Daratumumab remains a robust therapeutic option for extending progression-free and overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.